Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...

Our stories are reviewed by medical professionals to ensure you get the most accurate and useful information about your health and wellness. For more information, visit our medical review board. This ...

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with ...

Louisiana is making strides in breast cancer research, specifically focusing on triple-negative breast cancer. This type of cancer is known for occurring at an earlier age, spreading ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary ...

Beta-blockers may fight the progression of triple-negative breast cancer, researchers have found Getty Beta blockers — a commonly prescribed blood pressure medication — may be useful in stopping the ...